ReviewCancer cell international2025
GRP-based vaccines as a novel approach in cancer immunotherapy: mechanisms, challenges, and prospects.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose-regulated proteins (GRPs), key members of the heat shock protein (HSP) family, function as molecular chaperones that are upregulated under endoplasmic reticulum (ER) stress. Prominent GRPs such as GRP78, GRP94/gp96, GRP75, and GRP170 play a great role in cancer cell survival and progression by promoting protein folding, immune evasion, and resistance to therapy. Within the tumor microenvironment, which is characterized by hypoxia, acidosis, and nutrient deprivation, GRPs can facilitate critical processes including proliferation, angiogenesis, metastasis, and apoptotic resistance. Moreover, beyond their intracellular roles, GRPs have been found to possess considerable immunogenic potential when expressed on the cell surface or secreted. As a result, these findings have led to the development of GRP-based cancer vaccines that can elicit robust adaptive immune responses by chaperoning tumor antigens to antigen-presenting cells. Current evidence suggests GRP75 (HSPA9/mortalin) is less immediately tractable than ER-resident GRPs (78/94/170) for vaccine design, primarily owing to its mitochondrial localization and poor antigen accessibility. However, nanoparticle-mediated delivery or CRISPR-engineered surface expression could reposition it as a future target, pending advances in intracellular antigen presentation pathways. Preclinical models have demonstrated that GRP-based immunotherapy can induce cytotoxic T lymphocyte responses and tumor regression. Additionally, repurposing GRP-targeted strategies from infectious, autoimmune, and neurodegenerative disease contexts may offer promising translational avenues in the field of cancer. Despite encouraging results, challenges such as tumor heterogeneity, immune suppression, and delivery optimization have still remained. Therefore, future research should aim to increase antigen specificity, optimize vaccine formulations, and explore combinatory regimens to overcome resistance mechanisms in cancer cells. Overall, GRP-targeted vaccines represent a very compelling candidate in cancer immunotherapy with great potentials for clinical translation in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.